

ASH 2023: Dec 8 - 11; San Diego

Date	Start Time	End Time	Session Type	Speaker/Presenter	Session Title	Presentation Title	Location	Paper Number	
<b>Friday, Dec 8</b>									
12/8/23	11:00:00	14:00:00	Satellite Symposia	Peter A. Riedell, MD	Hitting the Mark? Targeted Antibody-Based Therapy for Diffuse Large B-cell Lymphoma		SDCC - Room 6DE		
12/8/23	13:30:00	14:00:00	Trainee Activities and Services	Emily K Curran, MD	ASH-a-Palooza	Blood Buddies: BMT Pediatric and Adult	Petco Park - Sections 122 and 124		
12/8/23	15:00:00	18:00:00	Satellite Symposia	Sonali M. Smith, MD	An Expert Guide to What's New and What's Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma		Marriott Marquis - Pacific Ballroom		
12/8/23	15:10:00	15:22:00	Scientific Workshop	Jason Xiaojun Cheng, MD, PhD	Post-Transcriptional Mechanisms Controlling Therapy Response	RNA:m5C Methyltransferases and RNA Epigenetics-Mediated Drug Resistance in Leukemia	SDCC - Room 7		
12/8/23	16:27:00	16:33:00	Scientific Workshop	Jill de Jong, MD, PhD	How Scientific Advances Impact Clinical Predictive Models and Recommendations	Retrospective Genetic Testing for Pediatric Patients with Presumed Idiopathic Aplastic Anemia Reveals Inherited Bone Marrow Failure Syndromes	SDCC - Room 29		
12/8/23	16:33:00	16:35:00	Scientific Workshop	Jill de Jong, MD, PhD	How Scientific Advances Impact Clinical Predictive Models and Recommendations	Q + A	SDCC - Room 29		
<b>Saturday, Dec 9</b>									
12/9/23	16:45:00	17:00:00	Oral	Tadeusz Kubicki	652. Multiple Myeloma - Clinical and Epidemiological - Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics	Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial	Grand Hyatt - Harbor Ballroom	Paper No: 0340	
12/9/23	17:30:00	19:30:00	Poster	Andrzej J Jakubowski, MD, PhD	652. Multiple Myeloma - Clinical and Epidemiological - Poster I	Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and D...	SDCC - Halls G-H	Paper No: 1982	
12/9/23	17:30:00	19:30:00	Poster	Hannah Johnston, MD	612. Acute Lymphoblastic Leukemias - Clinical and Epidemiological - Poster I	Socioeconomic Determinants and the Biology and Outcomes of Acute Lymphoblastic Leukemia in Adults	SDCC - Halls G-H	Paper No: 1468	
12/9/23	17:30:00	19:30:00	Poster	Alexandra E. Rojek, MD	613. Acute Myeloid Leukemias - Clinical and Epidemiological - Poster I	Treatment Patterns Among Patients with Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia after Intensive Induction Chemotherapy	SDCC - Halls G-H	Paper No: 1484	
12/9/23	17:30:00	19:30:00	Poster	Samuel J. Yates, MD, MSc	613. Acute Myeloid Leukemias - Clinical and Epidemiological - Poster I	Trial in Progress: Investigating the Prognostic Significance of Malnutrition and Sarcopenia in Older Adults with Acute Myeloid Leukemia	SDCC - Halls G-H	Paper No: 1493	
<b>Sunday, Dec 10</b>									
12/10/23	10:00:00	10:15:00	Oral	Tanner C. Martinez	501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis - Basic and Translational - Cell Fate Decisions and Fitness	CUX1 Levels Control Hematopoietic Stem Cell Fate and Plasticity	SDCC - Room 24	Paper No: 0399	
12/10/23	17:30:00	17:45:00	Oral	Peter A Riedell, MD	627. Aggressive Lymphomas - Clinical and Epidemiological - Aiming for the Right Target - Using CAR-T and Bispecifics in Aggressive Lymphomas	Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium	SDCC - Ballroom 20AB	Paper No: 0617	
12/10/23	18:00:00	20:00:00			634. Myeloproliferative Syndromes - Clinical and Epidemiological - Poster II		SDCC - Halls G-H		
12/10/23	18:00:00	20:00:00	Poster	Tara O. Henderson, MD	624. Hodgkin Lymphomas and T/NK cell Lymphomas - Clinical and Epidemiological - Poster II	AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymph...	SDCC - Halls G-H	Paper No: 3084	
12/10/23	18:00:00	20:00:00	Poster	Mirielle Nauman, PhD	631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia - Basic and Translational - Poster II	BCL-XI Represents a Novel Therapeutic Target in Type 2 Mutant Calr-Driven Myeloproliferative Neoplasms	SDCC - Halls G-H	Paper No: 3148	
12/10/23	18:00:00	20:00:00	Poster	Tadeusz Kubicki	652. Multiple Myeloma - Clinical and Epidemiological - Poster II	Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Len...	SDCC - Halls G-H	Paper No: 3344	
12/10/23	18:00:00	20:00:00	Poster	Alexandra E. Rojek, MD	615. Acute Myeloid Leukemias - Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies - Poster II	Intensive Induction Chemotherapy with or without Gemtuzumab Ozogamicin Among Patients with Core-Binding Factor Acute Myeloid Leukemia	SDCC - Halls G-H	Paper No: 2889	

12/10/23	18:00:00	20:00:00	Poster	Anand Ashwin Patel, MD	634. Myeloproliferative Syndromes - Clinical and Epidemiological - Poster II	Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies	SDCC - Halls G-H	Paper No: 3192	
12/10/23	18:00:00	20:00:00	Poster	Andrew Palmer, BS	906. Outcomes Researchâ€œMyeloid Malignancies - Poster II	The Impact of Air Pollutants on a Chicagoland Cohort of Patients with Acute Myeloid Leukemia	SDCC - Halls G-H	Paper No: 3806	
12/10/23	18:00:00	20:00:00	Poster	Andrzej J Jakubowiak, MD,PhD	653. Multiple Myeloma - Prospective Therapeutic Trials - Poster II	Updated Results of Talquetamab, a GPRC5Dâ€”CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Ph...	SDCC - Halls G-H	Paper No: 3377	
<b>Monday, Dec 11</b>									
12/11/23	10:00:00	11:00:00	Meet with editor	Geoffrey R Hill, MD,Olatoyosi Odenike	Meet the Blood Advances Editors (for in-person participants)		SDCC - Halls G-H - Blood Journals Studio	This session offers attendees the opportunity to meet with the associate editors of Blood Advances. Learn about recent changes to the journal as well as the submission and peer-review processes and policies. Seating is limited and available on a first-come, first-served basis.	
12/11/23	10:30:00	12:00:00		Matthew C. Cheung, MD,MSc	ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults		Grand Hyatt - Grand Hall C	Chair: Matthew C. Cheung, MD,MSc	
12/11/23	10:30:00	10:45:00	Oral/Special-Interest Session	Wendy Stock, MD	ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults	Initial Therapy for ALL in Adolescents and Young Adults	Grand Hyatt - Grand Hall C	Disclosure: No relevant conflicts of interest to declare.	
12/11/23	14:45:00	16:15:00	Oral	Sheng Li, PhD,Caner Saygin, MD	503. Clonal Hematopoiesis, Aging and Inflammation-From Omics to Discoveries		SDCC - Room 24	Moderator: Sheng Li, PhD	
12/11/23	14:45:00	15:00:00	Oral	Jie Liu, MBBS, MPH	503. Clonal Hematopoiesis, Aging and Inflammation-From Omics to Discoveries	Genetic Determinants of Clonal Hematopoiesis and Progression to Hematologic Malignancies in 479,117 Individuals	SDCC - Room 24	Paper No: 0811	
12/11/23	14:45:00	15:00:00	Oral	Andrew Srisuwananukorn, MD	803. Emerging Tools, Techniques and Artificial Intelligence in Hematology - Image-Based Machine Learning in Hematology	Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool	SDCC - Room 6CF	Paper No: 901	
12/11/23	15:45:00	16:00:00	Oral	Alan Cooper	621. Lymphomas - Translational â€œMolecular and Genetic - Insights into Lymphoma - Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics	A CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition	SDCC - Room 6DE	Paper No: 0851	
12/11/23	16:30:00	18:00:00	Oral	Mariam T. Nawas, MD,Brian C. Shaffer, MD	721. Allogeneic Transplantation - Conditioning Regimens, Engraftment and Acute Toxicities - Expanding the Donor Pool		SDCC - Ballroom 20AB	Moderator: Mariam T. Nawas, MD	
12/11/23	17:15:00	17:30:00	Oral	Gregory W Roloff, MD	705. Cellular Immunotherapies - Late Phase and Commercially Available Therapies - Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas - Clinical Trial and Real	Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)	SDCC - Room 6CF	Paper No: 1030	
12/11/23	18:00:00	20:00:00	Poster	Andrzej J Jakubowiak, MD,PhD	653. Multiple Myeloma - Prospective Therapeutic Trials - Poster III	Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)	SDCC - Halls G-H	Paper No: 4747	
12/11/23	18:00:00	20:00:00	Poster	Nabil Abou Baker, MD	901. Health Services and Quality Improvement - Non-Malignant Conditions - Poster III	Implementation of a Multipronged Intervention to Improve Inpatient Sickle Cell Disease Care	SDCC - Halls G-H	Paper No: 5062	
12/11/23	18:00:00	20:00:00	Poster	Tadeusz Kubicki	652. Multiple Myeloma - Clinical and Epidemiological - Poster III	Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Le...	SDCC - Halls G-H	Paper No: 4715	